Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17494211 | 0.94 | TAS1R3 (0.41) | TAS1R3TAS1R1TAS1R2TSHRMAPK1 | |
| SCHEMBL17494200 | 0.75 | ROCK2 (0.39) | TSHRPOLB | |
| SCHEMBL17494394 | 0.72 | SOS1 (0.40) | TAS1R3TAS1R1TAS1R2TSHRMAPK1 | |
| SCHEMBL505263 | 0.72 | TSHR (0.52) | TSHRMAPK1MAPT | |
| SCHEMBL19478140 | 0.71 | TSHR (0.43) | TAS1R3TAS1R1TAS1R2TSHRMAPK1 | |
| SCHEMBL17494203 | 0.70 | TAS1R3 (0.31) | TAS1R3TAS1R1TAS1R2TSHRMAPK1 | |
| SCHEMBL17494303 | 0.69 | LMNA (0.35) | TAS1R3TAS1R1TAS1R2TSHRMAPK1 | |
| SCHEMBL19200579 | 0.69 | TSHR (0.36) | TAS1R3TAS1R1TAS1R2TSHRMAPK1 | |
| SCHEMBL19200394 | 0.69 | TSHR (0.35) | TAS1R3TAS1R1TAS1R2TSHRMAPK1 | |
| SCHEMBL17494284 | 0.67 | YAP1 (0.40) | POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160726-B2 | Quinolone derivatives as antibacterials | NOVARTIS AG (CH) | 2018-12-25 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| EP-3177593-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | Novartis AG (CH) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016020836-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | TOP1, NQO2, TOP2A | TAS1R3 3900/4885TAS1R1 3563/4885TAS1R2 4117/4885 |
| US-10160726-B2 | Quinolone derivatives as antibacterials | TOP1, NQO2, TOP2A | TAS1R3 3900/4885TAS1R1 3563/4885TAS1R2 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.